The stock of Abzena PLC (LON:ABZA) reached all time low today, Nov, 2 and still has GBX 30.69 target or 10.00% below today’s GBX 34.10 share price. This indicates more downside for the GBX 46.62M company. This technical setup was reported by Barchart.com. If the GBX 30.69 PT is reached, the company will be worth GBX 4.66 million less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. The stock decreased 13.67% or GBX 5.4 on November 2, hitting GBX 34.1. About 27,956 shares traded hands or 206.00% up from the average. Abzena PLC (LON:ABZA) has declined 31.00% since April 4, 2016 and is downtrending. It has underperformed by 33.52% the S&P500.
More important recent Abzena PLC (LON:ABZA) news were published by: Businesswire.com which released: “Abzena plc: Placing to Raise £20 Million and Acquisition” on November 24, 2015, also Businesswire.com published article titled: “Abzena Plc: PacificGMP Makes Two Senior Appointments”, Businesswire.com published: “Abzena plc full year results: revenues up 74%, strong outlook within growing …” on June 14, 2016. More interesting news about Abzena PLC (LON:ABZA) was released by: Businesswire.com and their article: “Abzena plc: Adheron Therapeutics is Acquired by Roche for Its Therapeutic Antibody” with publication date: October 09, 2015.
Abzena plc is a life sciences company. The company has a market cap of 46.62 million GBP. The Firm provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It currently has negative earnings. It has a global customer base which includes biopharmaceutical companies, as well as large and small biotech companies and academic groups.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.